Kilpailijateknologia ADCs:istä?

https://www.cas.org/es-es/resources/cas-insights/unveiling-potential-antibody-drug-conjugate  

Ei tarvitse huolestua. Vaikka antibody-lääke-yhdistelmät tarjoavat 'Troijan hevosen' suoraan sairaaseen kudokseen, niihin liittyy ongelmia.

"In the ever-evolving landscape of cancer therapeutics, antibody-drug conjugates (ADCs) have emerged as a promising class of treatments. ADCs combine the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, offering a novel approach to targeted therapy. Antibody-drug conjugates have shown tremendous promise in the fight against cancer, with the potential to be a game-changer in the targeted treatment of a range of non-oncological indications.

Like immunotherapies such as immune checkpoint inhibitors, antibody-drug conjugates promise to revolutionize cancer treatment. However, the two classes of compounds operate through distinct mechanisms. While immunotherapies boost the patient's immune response against cancer cells, the antibody-drug conjugate operates as a 'Trojan Horse,' delivering a lethal strike directly to the cancer cells."

Kiinnostusta riittää ja aihetta tutkitaan myös syöpäsairauksien ulkopuolelta. ADC-markkinat olivat 8,6 mrd$ v. 2022 ja niiden odotetaan kasvavan 23,9 mrd$:iin v. 2032.

"The global antibody-drug conjugate market was estimated to be worth $8.6 billion in 2022 and is forecasted to reach $23.9 billion by 2032, growing at a CAGR of 10.7% in that time."

HAASTEITA: Valmistus käsittää useita vaiheita, mikä voi johtaa suuriin kustannuksiin. Antigeenin valinta tuottaa ongelmia, kaikilla syöpäsoluilla ei edes ole selkeästi määritettyjä antigeenejä.

"While the potential of antibody-drug conjugates is undeniable, there are several challenges and limitations that need to be addressed in their development. To start, the manufacture of antibody-drug conjugates involves multiple steps, including antibody production, drug synthesis, and conjugation. This complexity can lead to high manufacturing costs

Selecting suitable antigens remains another hurdle, as effective targeting relies on the antigen's specificity to cancer cells. This selectivity is crucial to ensure the precision of the therapy and minimize off-target effects. However, not all cancers have well-defined target antigens, and the heterogeneity of antigen expression within tumors can further complicate target selection."

Ja testitulokset eivät ole olleet kehuttavia:

  

 Faasi III:ssa 0-16%.

Percentage of ADC clinical trials in various phases for the treatment of specific solid tumors and hematological malignancies 

Kommentit

Tämän blogin suosituimmat tekstit

A Some, monopoli, molekyyliesimerkki

t Capital Markets Day

1 Toimiva lääke